Eli Lilly is pressing the lucrative weight loss market as it advances to a new and more convenient phase that promises to expand the attractiveness of its innovative drugs. The name of the Lilly News Club said that its daily obesity pill was successful in a late test for type 2 diabetes, sending actions that rise more than 15% in Thursday's session. The pill, known as Orforglipron, belongs to the booming drug class called LPG-1, which mimics an intestinal hormone to help regulate blood sugar and effectively suppress appetite. The main LPG-1 in the market, Lilly's zero for obesity and Mounjaro for type 2 diabetes, and full of obesity of Novo Nordisk and Ozempic by type 2 diabetes) are taken as injectables once a week. For investors, the most relevant details in Lilly's press release are about the tolerability and safety of the pill instead of how many pounds of patients in the orphorglipron pill they lost during the trial. The company said that the general security profile of the drug in the trial was “consistent with the established LPG-1 class,” added that no concerns about liver security were observed, in particular. Part of the reason for this approach is that patients with type 2 diabetes generally lose less weight in LPG-1s than non-diabetics with obesity; An orforglipron trial in the late stage that enrolled only people with obesity will be released at the end of this year, and that data will offer a better view to the amount of weight loss that the medication can achieve. There is also some unpredictability inherent with the chemistry behind the Oral LPG-1, said the CEO of Lilly, David Ricks, who added emphasis on the security profile. Undoubtedly, diabetic patients in the 40 -week trial still throw pounds in orforglipron. On average, participants lost 7.9% of their body weight, equal to approximately 16 pounds. Investors were waiting in the range of 5% to 6%, JPMorgan analysts estimated in a note last month, which they said would result in approximately 13% to 15% weight loss in the study focused on obesity at the end of this year. The best -expected weight loss performance for orforglipron in the diabetes trial and security results were to feed the increase in actions on Thursday, which increased the stock approximately 9.5% to date in a difficult 2025 for the general stock market. Even with the demonstration on Thursday, Lilly's shares were still approximately 12% below their closing record of $ 960 on August 30, 2024. In a note for clients on Thursday, Readink analysts said Orforgripron showed a security and efficacy similar to the Ozempic de Novo, a very encouraging sign. Novo is Lilly's main rival in the LPG-1 market, although a large number of drug manufacturers rush. Novo has some different weight loss pills in clinical trials, but their actions fell more than 8% on Thursday, an indication that investors are concerned about what Lilly's data means for the Danish drug manufacturer. Lly Nvo 1y Mountain Eli Lilly vs. Novo Nordisk 1 year of drug addicts and investors, equally, see weight loss pills as an important new border for the rapidly growing obesity market. In a CNBC interview earlier this year, Lilly's scientific director, Dan Skovronsky, explained why these types of medications should be useful for both patients and the company, which has faced numerous supply limitations by trying to meet the demand for GLP-1 injectables. “I am excited by [orforglipron] Not because it will give more weight loss or better tolerability or something, just because it is a pill and it is oral and that could help many people who can be reluctant to use an injectable or live in parts of the world where it is difficult to have cold chain sending. It is easier to do, etc. “Skovronsky said. In addition to expanding the obesity market to people who do not want Study in the late stage in which a patient may have developed a hepatic lesion induced by the drug that has a weight loss pill before in the development that is directed to a hormone different from that of LPG-1, and could look for other experimental drugs of the smallest players of profits of the first quarter of Eli Lilly on May 1 will help shed light on the performance of Mounjaro and Zepbound, along with the way executives are thinking about other blankets in pharmaceutical products, such as tariff and human services. The Trump administration has said that it is preparing “sectoral” tariffs on pharmaceutical products, although the details are still light on how they will see. The final result of Eli Lilly fortified his strong position in the obesity drug career: oforglipron cleared the security bar and exceeded expectations in weight loss, which is a good omen for what the obesity -centered trial will show at the end of this year. “It became a horse race after this,” said Jim Cramer at the Thursday morning meeting, although he had warning that Kennedy directed the HHS has made the regulatory climate towards obesity drugs more uncertain than before. Even so, as we currently know, Orforglipron seems like a safe and effective weight loss that can help the obesity market to reach its total commercial potential in the coming years. In particular, Lilly has strategically storing the Orforgripron inventory, which could help the company begin to receive the approval of US regulators. Lilly hopes to present Orforgripron for the approval of obesity at the end of this year, followed by a presentation of type 2 diabetes in 2026 (Jim Cramer's charitable trust is long. See here for a complete list of shares) as a subscriber for the CNBC investment club with Jim Cramer, you will receive a commercial alert before JIM makes a trade. Jim waits 45 minutes after sending a commercial alert before buying or selling an action in the portfolio of his charitable trust. If Jim has talked about an action on CNBC TV, wait 72 hours after issuing the trade alert before executing the operation. The information of the previous investment club is subject to our terms and conditions and privacy policy, together with our discharge of responsibility. There is no fiduciary obligation or duty, or is created, by virtue of receiving any information provided in relation to the investment club. No specific results or profits are guaranteed.
Eli Lilly and Company, headquarters of the pharmaceutical company in Alcobendas, Madrid, Spain.
Cristina Arias | Cover | Getty images
Eli Lilly It is hardening its control in the lucrative weight loss market as it advances in a new and more convenient phase that promises to expand the attractiveness of its innovative drugs.
